Download Sex steroid hormones and uterine fibroids

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Vectors in gene therapy wikipedia , lookup

Epigenetics in stem-cell differentiation wikipedia , lookup

Polycomb Group Proteins and Cancer wikipedia , lookup

Mir-92 microRNA precursor family wikipedia , lookup

NEDD9 wikipedia , lookup

Transcript
Sex steroid hormones and uterine fibroids
Serdar E Bulun, MD
JJ Sciarra Professor and Chair
Department of Obstetrics and Gynecology
Northwestern University Feinberg School of Medicine
250 E. Superior Street, Room 3-2306
Chicago, IL 60614
[email protected]
Uterine fibroid (leiomyoma), diagnosed in approximately 25% of all reproductive-age
women, is comprised of abnormal smooth muscle cells and abundant extracellular
matrix. They are dependent on ovarian steroids for growth and cause excessive
uterine bleeding, anemia, pelvic discomfort and recurrent pregnancy loss. Uterine
fibroids affect African-American women 3 times more often, at an earlier age and with
higher symptom severity. More than 70% of all fibroids bear a MED12 gene mutation
or a gross chromosomal defect. A single somatic mutation that alters the function of a
critical gene in a myometrial tissue stem-like cell may be the initiating event because
a distinct fibroid stem cell population carrying MED12 mutations is necessary for
steroid hormone-dependent rapid tumor growth. The majority of fully differentiated
uterine fibroid smooth muscle cells contain ample estrogen and progesterone
receptors. Estrogen and its receptor primarily function to induce progesterone
receptor, which mediates the proliferative actions of progesterone. Genome-wide,
progesterone receptor binds to thousands of DNA sites in fibroid smooth muscle cells
to regulate multiple genes and promote proliferation, survival and abnormal
production of extracellular matrix. These laboratory findings pertain because
treatment of patients with antiprogestins strikingly diminishes the tumor size and
associated symptoms. We revealed a distinct tumor progenitor cell population within
a leiomyoma with self-renewing capacity, which comprises only 5% of the tumor and
express stem cell markers. Only this particular cell population was indispensable for
robust tumor formation in response to estrogen and progesterone in vivo. These
cells, however, are estrogen and progesterone receptor-deficient but rich in the cell
surface receptors for cytokines and growth factors, suggestive of a paracrine
mechanism between these stem cells and fully differentiated fibroid smooth muscle
cells rich in estrogen/progesterone receptors. We seek to define the molecular
interactions between distinct uterine leiomyoma cell populations that are responsible
for
self-renewal,
proliferation,
and
estrogen/progesterone
responsiveness.
The overall hypothesis is that a small stem cell population, devoid of
estrogen/progesterone receptors, is essential for estrogen/progesterone-dependent
growth, and that steroid-initiated alterations in steroid receptor-expressing support
cells are transduced to the stem cells by cytokine or growth factor-mediated signals.
We discuss the cellular and molecular mechanisms responsible for the therapeutic
effects of anti-progestins on uterine fibroids.